Curcumin as a therapeutic agent in leukemia.


Journal

Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222

Informations de publication

Date de publication:
08 2019
Historique:
received: 01 11 2018
accepted: 18 12 2018
pubmed: 5 1 2019
medline: 22 5 2020
entrez: 5 1 2019
Statut: ppublish

Résumé

Leukemia comprises a group of hematological malignancies responsible for 8% of all cancers and is the most common cancer in children. Despite significant improvements in leukemia treatment, the efficacy of conventional chemotherapeutic agents is low and the disease carries a poor prognosis with frequent relapses and high mortality. Curcumin is a yellow polyphenol compound with diverse pharmacological actions including anticancer, antioxidant, antidiabetic, anti-inflammatory, immunomodulatory, hepatoprotective, lipid-regulating, antidepressant, and antiarthritic. Many cellular and experimental studies have reported the benefits of curcumin in treating leukemia. Curcumin's anticancer effects are exerted via various mechanisms. Here, we review the effects of curcumin on various types of leukemia whilst considering its mechanisms of action.

Identifiants

pubmed: 30609023
doi: 10.1002/jcp.28072
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antineoplastic Agents 0
Curcumin IT942ZTH98

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

12404-12414

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Hamideh Kouhpeikar (H)

Department of Hematology and Blood Bank, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Iran.

Alexandra E Butler (AE)

Diabetes Research Center, Qatar Biomedical Research Institute, Doha, Qatar.

Faeze Bamian (F)

Department of Hematology and Blood Bank, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Iran.

George E Barreto (GE)

Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile.

Muhammed Majeed (M)

Sabinsa Corporation, East Windsor, New Jersey.

Amirhossein Sahebkar (A)

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH